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Marine organisms produce a vast diversity of metabolites with biological activities useful for humans, e.g. cytotoxic, antioxidant,
anti-microbial, insecticidal, herbicidal, anticancer, pro-osteogenic and pro-regenerative, analgesic, anti-inflammatory,
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have been characterized from marine organisms, but many more are yet to be uncovered, as the vast diversity of biota in the
marine systems remains largely unexplored. Since marine biotechnology is still in its infancy, there is a need to create effective,
operational, inclusive, sustainable, transnational and transdisciplinary networks with a serious and ambitious commitment for
knowledge transfer, training provision, dissemination of best practices and identification of the emerging technological trends
through science communication activities. A collaborative (net)work is today compelling to provide innovative solutions and
products that can be commercialized to contribute to the circular bioeconomy. This perspective article highlights the importance
of establishing such collaborative frameworks using the example of Ocean4Biotech, an Action within the European Cooperation in
Science and Technology (COST) that connects all and any stakeholders with an interest in marine biotechnology in Europe and
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Abstract 85 
Marine organisms produce a vast diversity of metabolites with biological activities useful for 86 
humans, e.g. cytotoxic, antioxidant, anti-microbial, insecticidal, herbicidal, anticancer, pro-87 
osteogenic and pro-regenerative, analgesic, anti-inflammatory, anti-coagulant, cholesterol-lowering, 88 
nutritional, photoprotective, horticultural or other beneficial properties. These metabolites could help 89 
satisfy the increasing demand for alternative sources of nutraceuticals, pharmaceuticals, 90 
cosmeceuticals, food, feed, and novel bio-based products. In addition, marine biomass itself can 91 
serve as the source material for the production of various bulk commodities (e.g. biofuels, 92 
bioplastics, biomaterials). The sustainable exploitation of marine bio-resources and the development 93 
of biomolecules and polymers are also known as the growing field of marine biotechnology. Up to 94 
now, over 35,000 natural products have been characterized from marine organisms, but many more 95 
are yet to be uncovered, as the vast diversity of biota in the marine systems remains largely 96 
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unexplored. Since marine biotechnology is still in its infancy, there is a need to create effective, 97 
operational, inclusive, sustainable, transnational and transdisciplinary networks with a serious and 98 
ambitious commitment for knowledge transfer, training provision, dissemination of best practices 99 
and identification of the emerging technological trends through science communication activities. A 100 
collaborative (net)work is today compelling to provide innovative solutions and products that can be 101 
commercialized to contribute to the circular bioeconomy. This perspective article highlights the 102 
importance of establishing such collaborative frameworks using the example of Ocean4Biotech, an 103 
Action within the European Cooperation in Science and Technology (COST) that connects all and 104 
any stakeholders with an interest in marine biotechnology in Europe and beyond. 105 
Introduction 106 
During four billion years of evolution in the ocean, marine organisms have evolved in their 107 
environment to biosynthesize a plethora of biopolymers and biomolecules. These include the unique 108 
secondary metabolites that are produced in response to environmental stimuli. They play important 109 
biological roles in improving competitiveness, providing chemical defense against predators or 110 
competitors and facilitating reproductive processes. These biomolecules are not always essential for 111 
the growth and development of the organism, but they are important for the survival and well-being 112 
in its environment. Furthermore, some compounds such as marine enzymes have properties essential 113 
for industrial applications like thermostability or tolerance to a diverse range of pH and salinity 114 
conditions. These properties are being utilized in various industries such as in the food, animal feed, 115 
leather, textile and horticulture industries, and in bioconversion and bioremediation processes (Rao et 116 
al., 2017). Marine biotechnology appeared in the 1960s and 1970s when scientists realized the 117 
potential of living organisms and their natural products for industrial exploitation (Dias et al., 2012). 118 
Initially, the investigation of marine ecosystems relied on the easily accessible organisms like corals 119 
and sponges as well as macroalgae that have high biomass levels and were representative of targeted 120 
ecosystems (Greco and Cinquegrani, 2016). Therefore, most of the known natural products deriving 121 
from the marine environment were initially isolated from macro-organisms. On realizing that marine 122 
microbial biodiversity is vast, largely underexplored and unexploited, the application of marine 123 
microbial biotechnology aiming to valorize marine resources is a natural step forward in the 124 
development of the biotechnology sector.  125 
For a long time, it has been considered that only around 1% of the whole marine microbial 126 
population could be cultured under laboratory conditions (Vartoukian et al., 2010). However, recent 127 
findings suggest the percentage of culturable microbial population is higher; an estimated 13% - 78% 128 
of genera are cultured, depending on the environment (Lloyd et al., 2018). For example, 129 
environments with high human engagement and disease-driven research benefit from greater 130 
culturing effort (Steen et al., 2019; Lloyd et al., 2018). Since many cells in nonhuman environments 131 
belong to novel phyla, new culturing approaches and innovations will increase the percentage of 132 
uncultured microbes (Steen et al., 2019). Culture-independent methods using omics approaches are 133 
nowadays used to detect microorganisms that are yet uncultured. These methods include high-134 
throughput sequencing, metagenomics, transcriptomics, proteomics, metabolomics and 135 
bioinformatics resources for the identification of organisms and elucidation of metabolic pathways 136 
responsible for production of chemical compounds, as well as DNA-based or heterologous 137 
expression systems. Microbial identification is only an initial step and additional research is essential 138 
to develop cultivation techniques to obtain the necessary biomass in a sustainable manner. Next, 139 
biochemical and genetic engineering methods are required for the production of high quantities and 140 
quality of proteins, marine oils and other secondary metabolites of interest. Figure 1 provides a 141 
schematic representation of parameters that should be considered for the whole bioprospecting 142 
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process, starting from the selection of marine organisms, for their cultivation prior to their utilization 143 
for the biosynthesis of high-value bio-components and for investigation of their biological potential 144 
in various industries.  145 
Natural products are currently the most common source of therapeutic agents. The World Health 146 
Organization estimates that approximately 80% of the world’s population uses remedies based on 147 
natural products to treat their basic health problems. Over 35,000 bioactive compounds have been 148 
isolated and chemically characterized from marine organisms since the 1960s (Lindequist, 2016). 149 
While before 1985 less than 100 natural products were discovered annually, in the late 1990s, this 150 
number rose to over 500 new products discovered yearly up to over 1,000 since 2008, mainly due to 151 
the advances in analytical methods (Carroll et al., 2019; Lindequist, 2016). The application of new 152 
dereplication strategies using mass spectrometry (MS) and the use of high-resolution Nuclear 153 
Magnetic Resonance (NMR) spectrometers with cryoprobes have enabled the discovery of new 154 
natural products even at the nanomole scale (Klitgaard et al., 2014). The most common approach 155 
used for the discovery of new marine bioactive chemical entities involves the screening of crude 156 
extracts or partially purified fractions of similar polarities against selected test organisms or 157 
therapeutic targets, followed by the purification and the structure elucidation of the active 158 
ingredients. The purification of metabolites is usually performed by means of chromatographic 159 
separation techniques combined with high-resolution MS based approaches that allow a rapid and 160 
accurate identification of the molecular mass and formulae of bioactive compounds. These methods 161 
are becoming a gold standard for the rapid and reliable dereplication of natural product extracts or 162 
fractions (Gaudêncio and Pereira, 2015).  163 
The unique structural architecture and broad range of activities exhibited by marine metabolites have 164 
caught the attention of the scientific community. This has resulted in the development of research 165 
programs promoting innovation and industrial uptake along with the creation of new jobs and of a 166 
competitive environment for biotechnology-oriented enterprises as stated in the Blue Growth 167 
Strategy of the European Union (EU). This orientation is in line with the strategy for “A sustainable 168 
bioeconomy for Europe: strengthening the connection between economy, society and environment” 169 
which is a 2018 update from the original 2012 Bioeconomy Strategy by the European Commission 170 
(EC). The strategy aims to create a more innovative, resource-efficient and competitive society that 171 
will reconcile drug discovery and food security with the sustainable and economically viable use of 172 
renewable resources for industrial purposes while ensuring environmental protection.  173 
Prerequisites for marine biotechnology (Figure 2) 174 
Sustainability. There are two sustainability levels that must be considered to effectively implement 175 
marine biotechnology in practice: (i) environmental and (ii) supply sustainability. (i) Environmental 176 
sustainability tackles the main sources of marine biomass which come either from species harvested 177 
in nature or from those that can be cultivated. It is especially relevant when wild stocks are the only 178 
source of supply and they are over-harvested, or where targeted marine species are rare, in the deep, 179 
or difficult to re-sample. The harvesting/sourcing of any target species should thus not threaten 180 
marine biodiversity and the future availability of target species. To minimize the environmental 181 
impact, the biotechnology community should consider valorizing side and waste streams and co-182 
products, target sustainably cultured marine organisms and those that are sufficiently productive to 183 
supply specific high added-value biomolecules. (ii) Sustainable supply of biomolecules represents 184 
key bottlenecks, as they are usually present in trace amounts. To guarantee a sustainable sourcing and 185 
production of target compounds, biologically active molecules or whole organisms should therefore 186 
be considered in a life cycle assessment and a multi-risk environmental analysis context. This will 187 
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attain a global evaluation including environmental, health and economic aspects for both the 188 
biological (sourcing) and technical (supplying) cycle. Industrial symbiosis and circular economy 189 
approaches must therefore be applied to find sustainable ways for utilization of marine bioresources 190 
(blue growth) using green production techniques that economize on exhaustible resources (green 191 
growth, Rodrik, 2014).  192 
Industry. Marine biotechnology generates various products and services, from the production of 193 
biofuels, food, feedstuffs and products for use in agriculture (high-volume, low-value and low-risk 194 
products), to the discovery of new biomaterials, cosmetics, nutraceuticals and pharmaceuticals (low-195 
volume, high-value and high-risk products). Research and development investments for the discovery 196 
of marine-derived drugs entail high levels of capital expenditure and risk tolerance, as they require 197 
the use of state-of-the-art infrastructures and many years of basic and applied research. Despite some 198 
limitations, there are successful examples, as to date there are ten approved drugs, one example being 199 
trabectedin (ET-743), a product isolated from a Caribbean sea squirt Ecteinascidia turbinata, which 200 
is used for the treatment of advanced soft tissue sarcoma. This product first reached the market in 201 
2007, after 20 years of research (Cuevas and Francesch, 2009). In practice, out of every 2,500 202 
analogs from the marine environment that enter preclinical testing, only one may be safe and 203 
effective enough to reach clinical use (Gerwick and Fenner, 2013). There is a collaboration and 204 
communication gap between raw ideas and materials and their potential laboratory innovation and 205 
commercialization (Datta et al., 2014). This is being tackled by adopting three different strategies. (i) 206 
Firstly, by stimulating public-private partnerships in consortia that apply for research and innovation 207 
funding (such as Horizon 2020 and Horizon Europe, Europe’s biggest research and innovation 208 
funding resource). (ii) Another alternative are the business incubators (such as Rocket57 in Northern 209 
Europe1), think tanks or stakeholder events that are often regionally financed to answer strategic 210 
regional developmental priorities and present a contact point for joining researchers, small and 211 
medium enterprises, industrial representatives and investors. (iii) Financial stimulation of networking 212 
activities (the example of COST Action Ocean4Biotech is presented in the next chapter of this 213 
article). The global marine biotechnology market is expected to reach ~$6.4 billion by 20252 and it 214 
currently represents only ~1% of the whole biotechnology market. Noteworthy, the oceans cover 215 
over 70% of the Earth’s surface and contain an estimated 25% of the world’s species (Mora et al., 216 
2011), of which most are unknown and undervalorized. Hence, the marine biotechnology market is 217 
expected to expand at a much higher pace when high-throughput techniques and the collaboration 218 
between industry, science, general public and policy makers will be routinely used. The predominant 219 
players in the European marine biotechnology consist of some 140 micro SMEs (estimated by Ecorys 220 
in 2014) and academia that lack the financial stability necessary for sustained and long-term cutting-221 
edge research. 222 
Scientific community. To fully explore the ocean and its biota, the current screening and/or 223 
cultivation approaches of marine organisms of interest for biotechnological applications need to be 224 
optimized. High-throughput techniques produce vast amounts of data and can uncover the 225 
biodiversity and the metabolic potential of marine organisms. Hence, knowledge on data 226 
management, processing and data analysis to maximize the quality and quantity of resulting 227 
information needs to be advanced. Experts from the field of statistics, bioinformatics and 228 
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databases should be integrated, harmonized and publicly available to prevent duplication of efforts, 230 
reduce the overall costs and support the discovery process.  231 
General public. While the world population is rising and is expected to reach over 8.5 billion by 232 
2030, bioresources and available areas for cultivation and manufacture are declining. Hence, there is 233 
a growing demand for additional sources of food, drugs and chemicals. Marine biotechnology has the 234 
potential to mitigate these needs both by increasing the current production and by introducing new 235 
products in the food, feed, pharmaceutical, nutraceutical, healthcare, welfare, biomaterials and energy 236 
sectors. Nowadays, consumers expect innovative, efficient, safe, sustainable, ethical, financially and 237 
environmentally friendly solutions. We need to raise public awareness and improve communication 238 
to a broad audience regarding the benefits of marine biotechnology products to gain consumers’ 239 
interest in eco-friendly products that meet high standards of sustainability. 240 
Policy makers. Some national, regional and global strategies and guidelines are already in place to 241 
recommend investment into marine biotechnology and stimulate networking and transdisciplinary 242 
collaboration at the international level. These include the United Nations (UN) sustainable 243 
development goals3, national and EU legislation that must be developed and harmonized. The UN 244 
Convention on the Law of the Sea4 sets the rules for the exploitation, conservation and management 245 
of living marine resources. The Nagoya Protocol on Access to Genetic Resources and Benefit 246 
Sharing provides a legal framework aimed at creating transparency for those interested in the 247 
production and exploitation of genetic materials. Marine biotechnology development needs also to 248 
comply with the Habitats Directive (92/43/EEC) on the conservation of natural habitats and of wild 249 
fauna and flora, the Marine Strategy Framework Directive (MSFD) (2008/56/EC, CD 2017/848) 250 
establishing a framework for community action in the field of marine environmental policy, the EU 251 
Water Framework Directive – WFD (Directive 2000/60/EC), and the Maritime Spatial Planning 252 
Directive (2014/89/EU) for the planning of multiple uses of the maritime and coastal areas. 253 
Biomolecules and their production processes must also comply with specific regulations related to 254 
the targeted application (e.g. EU 2015/2283 Novel Foods and Ingredients, EC No 1223/2009 255 
Cosmetic Regulation, EC No 1924/2006 Nutrition and Health Claims, EC No 1907/2006 REACH 256 
Regulation, among others). The widespread acceptance and certification of these novel compounds is 257 
a rigorous and time-consuming process where legislative documentation might need updating as 258 
novel compounds are being identified. It is thus necessary to encourage collaboration among 259 
scientists and policy makers, as outlined during the UNESCO High-Level Conference on the Ocean 260 
Decade (2018). Moreover, intellectual property strategies need to be established and agreed upon to 261 
conduct research in accordance with ethical recommendations for bioprospecting in the open ocean 262 
and beyond the national jurisdictions covered by the Nagoya protocol. 263 
The establishment of a collaborative network as a solution for advancing marine 264 
biotechnology: COST Action Ocean4Biotech 265 
Efficient and sustainable exploitation of the ocean’s potential is possible only if industrial actors, 266 
researchers, the general public, policy makers and environmental experts work together. This direct 267 
interaction among different stakeholders across different countries is not always possible and limited 268 
programs have been supported until today that allow a minimal direct transdisciplinary interaction 269 
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From this viewpoint, the EU COST program that was established in 1971 represents an excellent 271 
opportunity for the creation of research networks on diverse topics, called COST Actions. These 272 
networks offer an open space for collaboration among stakeholders across Europe (and beyond), 273 
thereby catalyzing research advancement and innovation5. One of the recently approved Actions is 274 
CA18238 – European transdisciplinary networking platform for marine biotechnology 275 
(Ocean4Biotech)6. The motivation behind creation of this network is included in the SWOT analysis 276 
(see Supplementary Table S2 and the discussion therein). Ocean4Biotech is an international, unique 277 
and inclusive network that gathers experts from transdisciplinary fields of exact and natural sciences, 278 
social sciences and humanities, giving the Action participants the opportunity to work together and 279 
share their experiences creating a spill-over effect to foster marine biotechnology and bioeconomy in 280 
a sustainable way. Ocean4Biotech will apply the Responsible Research and Innovation Roadmap 281 
(Theodotou Schneider, 2019) involving scientists, citizens, policy makers and industry in the co-282 
creation of knowledge and in the establishment of sustainable collaborative networks. 283 
Notably, Ocean4Biotech builds upon existing knowledge from current and past projects and 284 
initiatives (see Supplementary Table S1). It aims to establish strong collaborations to avoid the 285 
duplication of efforts. The difference between Ocean4Biotech and the current and past efforts is this 286 
Action is envisaged as a “connecting-the-dots” funnel initiative that will gather scientists and 287 
professionals from all areas related to the marine biotechnology field. This enables a wider approach 288 
aiming to facilitate the circular economy in the marine biotechnology sector. Researchers from all 289 
fields and levels of expertise relevant to marine biotechnology will have the opportunity to 290 
participate in the Action and will be included in knowledge exchange activities (between the 291 
scientific fields as well as within, e.g. senior-to-junior knowledge transfer), establishing new 292 
collaborations and having an opportunity for career advancement. The developments from this COST 293 
Action can impact the industrial sector, and in turn will most likely influence governance boards. 294 
However, the efforts of Ocean4Biotech to establish connections between its members and linkages 295 
with other initiatives will not be possible without proactive science communication, extensive 296 
dissemination along with active engagement and outreach activities. Efficient communication will 297 
enable informing on the activities and objectives of the Action and will attract researchers to prepare 298 
and initiate new collaborations that will span beyond the lifetime of Ocean4Biotech. 299 
How will Ocean4Biotech foster advances in the field of marine biotechnology? 300 
There are five general objectives within the Ocean4Biotech COST Action: 301 
1. Description of marine biodiversity. Knowledge of marine biodiversity is still limited. Moreover, 302 
there is a large interregional variability in species distribution and in their taxonomic knowledge. The 303 
lack of experts in marine species taxonomy, duplicates/redundancies/inconsistencies in the primary 304 
nucleotide databases, lack of type species and polyphyly of traditionally established taxa result in 305 
many misidentified or unidentified species/strains (many of which hold great potential for 306 
biotechnological applications). These are also important challenges to marine natural product 307 
programs. Hence, human resources, research effort, time and cost-efficient methods are needed to 308 
overcome the current gap in knowledge on biological and chemical diversity in marine ecosystems. 309 
These may be addressed by high-throughput methods that facilitate the discovery, classification and 310 
supply of organisms. However, high-throughput methods for biodiversity monitoring have not been 311 
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bioinformatics pipelines and big data analyses are changing the landscape for marine biotechnology, 313 
as around 18,000 new species are uncovered yearly7. Ocean4Biotech will propose operating 314 
procedures for uncovering the biodiversity using high-throughput methods, such as DNA barcoding 315 
approaches (Leese et al., 2016). These methods can then be combined with a more quantitative 316 
assessment by in situ hybridization techniques that allow the quantification and localization of 317 
specific microbial clusters within the environmental matrices. Such biodiversity assessment provides 318 
crucial information for subsequent monitoring and exploitation of marine organisms. The 319 
environmental impacts of such biological prospecting are considered minimal at the early stages of 320 
sampling, where the size of samples collected is small. Moreover, the standardization of the 321 
biodiscovery process is necessary as chemodiversity, even in the same taxa, greatly varies along 322 
geographical and environmental gradients, as well as seasonally and timely along the life cycle of 323 
organisms. 324 
2. Natural product discovery is a process involving separation techniques in parallel with biological 325 
screening, followed by structure elucidation of the pure bioactive metabolites. If the target compound 326 
from a given species shows biotechnological potential, scale-up production and supply will certainly 327 
increase the environmental impact. However, the organic synthesis of the compound (although time-328 
consuming and expensive) and/or production of the compound of interest using biological synthesis 329 
generally overcome the need for repeated collection and over-exploitation of the natural ecosystem. 330 
Therefore, Ocean4Biotech will build a compendium of pipelines, i.e. methods and procedures, 331 
detailed on a case study basis, starting from the creation of marine biorepositories, the identification 332 
of the collected species using integrative systematics, screening for specific bioactivities for selected 333 
industries, identification of the bioactive metabolites and their sustainable production, business plan 334 
development, marketing strategy, where legal and ethical aspects to be considered along with 335 
adherence to strict guidelines for protection of the environment and sustainability. These pipelines 336 
will serve as guidelines and tutorials for future product development and will enable the transfer of 337 
knowledge between disciplines. These pipelines will highlight the complementary transdisciplinary 338 
aspect of marine biotechnology and as a link with other sectors of biotechnology. According to the 339 
principles sustainability the supply chain decision-making will require the inclusion of social and 340 
economic aspects together with environmental aspects. Thus, the Action will apply an integrated 341 
framework for Life Cycle Sustainability Assessment (LCSA). Wherever possible, it will combine 342 
physical LCA considering different environmental impact categories (e.g. climate change, 343 
eutrophication or acidification) at different life-cycle levels (partial LCA) with social LCA (SLCA) 344 
and Life Cycle Costing (LCC), based on UNEP/SETAC guidelines. The approach used in this Action 345 
will build on existing models (Perez-Lopez et al., 2018). It will also follow the methodological 346 
framework for conducting LCA as outlined by the International Standards Authority (ISO) 14040 347 
series. 348 
3. Sharing infrastructure. There is an increasing need to create a bridge between research and 349 
innovation capabilities from the academia and business sectors. This includes the availability of the 350 
research infrastructure, thereby providing access to a range of new tools and facilities to allow marine 351 
biotechnology to thrive. Many of the tools and techniques used in marine biotechnology are widely 352 
used in other areas of science and technology. Engaging in collaborative research projects is one way 353 
of providing access to these facilities and encouraging multidisciplinary research. Ocean4Biotech 354 
will enable the diverse actors to share their expertise and infrastructure, mostly through short-term 355 
scientific missions and new collaborative activities. Preference will be given to users from the less 356 
 
7 https://www.eurekalert.org/pub_releases/2018-05/scoe-elt051718.php 
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research-intensive countries8 or early career investigators that need access to state-of-the-art 357 
analytical equipment, microbial cultures or screening facilities.  358 
4. Responsible Research and Innovation. The ocean should be monitored, valorized and governed 359 
in a sustainable manner to generate the maximum benefit to science and society but limiting the 360 
negative footprints on the marine environment. This will be addressed within the Action by adopting 361 
the Responsible Research and Innovation (RRI) concept, which is based on six pillars.  362 
(i) Ethics. We are all responsible for the stability and resilience of the Earth systems (Barbier et al., 363 
2018). Accordingly, ethical issues and challenges will be identified, addressed and used to advocate 364 
for protection of marine ecosystems and promote responsible resource management and 365 
environmental policies together with societal awareness.  366 
(ii) Open access. To efficiently co-create knowledge and capitalize from previous research, it is vital 367 
to consider transparency, efficiency, traceability, access to data, reciprocal relations, biosafety, nature 368 
conservation and transfer of knowledge to third countries.  369 
(iii) Gender equality will be promoted throughout the Action by empowering especially early career 370 
and female colleagues to apply for managerial roles and in the future establish and lead consortia for 371 
valorization of marine biotechnology products.  372 
(iv) Governance. Although the marine biodiversity has no borders, access to natural resources is 373 
framed under the Convention of Biological Diversity, promoting the conservation of biodiversity, the 374 
sustainable use of biological entities and their fair and equitable sharing. The latter is also covered in 375 
the Nagoya Protocol, which provides a legal framework for the fair and equitable sharing of benefits 376 
arising from the use of genetic resources which may sometimes delay or block certain research 377 
activities.  378 
(v) Public engagement. Action participants will employ communication tools and different activities 379 
to further inform legislative authorities, researchers and industry with the aim of facilitating the 380 
regulatory requirements that are sometimes a bottleneck to transnational collaboration.  381 
(vi) Science education. We will focus many of our activities into education of the next generation of 382 
researchers (i.e. early career investigators), with a special focus on the countries that are less research 383 
intensive, i.e. the so-called inclusiveness target countries9. These countries have developed their 384 
national strategic priorities in the frame of the EU Smart Specialization Strategy (S3), aiming to 385 
ensure a balanced development between regions10. Since marine biotechnology, including its 386 
products and applications, is well represented in all national S3 priorities, the timing is perfect to 387 
develop capacity-building educational opportunities that span beyond the traditional academic 388 
curricula. We will enable closing the educational gaps in three ways. (i) By short term scientific 389 
missions, which are mobility activities that involve a direct hands-on interaction and experience 390 
abroad. (ii) By offering financial opportunities for active participation in conferences that target any 391 
of the marine biotechnology related topics. (iii) Importantly, our trainings and workshops, that will 392 
be publicly promoted, will cover topics that integrate academy, technological centers and industry (as 393 
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strategy will avoid the risk of training a marine-related workforce that the market may not absorb 395 
(EuroMarine Working Group, 2019).  396 
5. Knowledge co-creation and integration. (i) The Action will be geographically inclusive as it will 397 
produce an open-access database of exploitable species for marine biotechnology in the 398 
Ocean4Biotech participating countries. In addition to the World Register of Marine Species 399 
(WoRMS11), this Action participants will focus on those species with putative biotechnological 400 
potential. (ii) The Action will be inclusive in the biological sense and include species regardless of 401 
the kingdom (from bacteria and algae to zooplankton and other species that are suitable for 402 
exploitation). (iii) Methodologically, the participants will integrate all levels of the biotechnological 403 
pipeline; from bioprospecting to cultivation, biological screening, compound isolation and 404 
optimization of the isolation process, and structure elucidation. (iv) This is a truly transdisciplinary 405 
Action, integrating expertise and including experts from various fields: marine (micro)biology, 406 
chemistry, food science, agriculture, pharmacology, medicine, environmental protection, engineering, 407 
energy, data science, omics techniques, statistics, law, policy making, economy, business planning, 408 
and more. The network will transfer knowledge from traditional academic institutions to exploitation 409 
industries leading to the elaboration of ecosystem services linked to policy makers’ priorities, 410 
citizens, industry and SMEs. 411 
Conclusion 412 
This Ocean4Biotech COST Action will contribute to the implementation of the Bioeconomy Strategy 413 
and the European Green Deal12. It will also mainstream the responsible research and innovation 414 
principles among the scientific and industry communities to foster the interaction between marine 415 
scientists and other marine biotechnology stakeholders, including the general public. Such interaction 416 
will be multidirectional rather than top-down and co-creative instead of just being introduced by the 417 
authorities and/or knowledge holders. Outreach and communication activities will provide 418 
information to the broad community and improve their capacity to understand the challenges and 419 
opportunities to make appropriate decisions in the field of marine biotechnology. An inclusive, 420 
integrative approach is essential to catalyze the expansion of marine biotechnology in Europe and 421 
worldwide and to finally harvest the products of this promising field of research. Finally, the 422 
establishment of interdisciplinary connections and collaborations during Ocean4Biotech’s lifetime 423 
will not only lead to future research collaborations that include industrial representatives as well, but 424 
also provide establishment of communication channels with policymakers, governments, and other 425 
stakeholders, including the public. This will eventually enable beneficial social and environmental 426 
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Supplementary Materials 523 
Supplementary Table S1: Examples of the past and current international initiatives in the field of 524 
marine biotechnology in Europe. The level column represents the targeted involvement within each 525 
initiative (industry, research community, legislative authorities, general public, environment 526 
protection; they are presented in Figure 2 and in the main text).  527 
Supplementary Table S2: A SWOT analysis used to plan and assess the necessity of establishing 528 
marine biotechnology interdisciplinary networks such as COST Action CA18238 (Ocean4Biotech). 529 
 530 
Figure legends 531 
Figure 1: Schematic representation of a bioprospecting protocol for the extraction of valuable 532 
bioactive compounds from marine organisms (adapted from Galanakis, 2019). 533 
Figure 2: Major prerequisites for the establishment of sustainable actions in marine biotechnology. 534 
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